未登录

K

Konrad Paszkiewicz

University of Exeter

H指数:38

被引数:4,995

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The VISTA blocking antibody HMBD-002 promotes type-I interferon signaling and drives anti-tumor responses through macrophage reprograming and cytotoxic CD8+T cell activation

CANCER RESEARCH

IF16.6

2024-03-220

PRE

A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations

CANCER RESEARCH

IF16.6

2024-03-220

PRE

A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling

靶向HER3的单克隆抗体HMBD-001的Ib期研究，在HER3信号传导遗传畸变患者中进行或不进行化疗

ANNALS OF ONCOLOGY

IF65.4

2023-11-010

PRE

Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected pre-clinical models of squamous cell carcinomas

CANCER RESEARCH

IF16.6

2023-04-040

PRE

From crisis to recovery: A complete insight into the mechanisms of chlorine injury in the lung

IF5.1

2023-01-012

OAAI

ANTI-VISTA ANTIBODY HMBD-002 REPROGRAMS TUMOUR ASSOCIATED MACROPHAGES AND PROMOTES CYTOTOXIC T CELL RESPONSE

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2022-11-071

OA

Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2022-02-0735

OAAI

An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-12-015

PRE

Transcriptomic analysis of the trade-off between endurance and burst-performance in the frog Xenopus allofraseri

IF3.7

2021-03-232

OAAI

10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2020-02-0616

OAAI

Common Host Responses in Murine Aerosol Models of Infection Caused by Highly Virulent Gram-Negative Bacteria from the Genera Burkholderia, Francisella and Yersinia

IF3.3

2019-09-215

OAAI

A ZEBRAFISH MODEL OF CLOZAPINE EXPOSURE: DRUG-INDUCED TRANSCRIPTOMIC CHANGES IN THE BRAIN

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2019-01-010

PREAI

The Culture Environment Influences Both Gene Regulation and Phenotypic Heterogeneity in Escherichia coli

培养环境影响大肠杆菌的基因调控和表型异质性

FRONTIERS IN MICROBIOLOGY

IF4.5

2018-08-1543

OAAI

Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody

CANCER RESEARCH

IF16.6

2018-07-018

PRE

Genome-wide chromatin mapping with size resolution reveals a dynamic sub-nucleosomal landscape in Arabidopsis

IF3.7

2017-09-1327

OAAI

Molecular epidemiology of Pseudomonas aeruginosa in an unsegregated bronchiectasis cohort sharing hospital facilities with a cystic fibrosis cohort

IF7.7

2017-08-2612

OAAI

Meiotic Genes in Colpodean Ciliates Support Secretive Sexuality

GENOME BIOLOGY AND EVOLUTION

IF2.8

2017-07-117

OAAI

Decay of the glycolytic pathway and adaptation to intranuclear parasitism within Enterocytozoonidae microsporidia

ENVIRONMENTAL MICROBIOLOGY

IF4

2017-04-1283

OAAI

A Pelagic Microbiome (Viruses to Protists) from a Small Cup of Seawater

IF3.5

2017-03-1713

OAAI

A Noise Trimming and Positional Significance of Transposon Insertion System to Identify Essential Genes in Yersinia pestis

SCIENTIFIC REPORTS

IF3.9

2017-02-068

OAAI